Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine.

ABSTRACT:

Background

Little is known about the safety of SARS-CoV-2 vaccination in patients with rheumatic musculoskeletal disease (RMD). We evaluated the occurrence of adverse events following immunization (AEFI) in RMD patients and heathy subjects who received anti-SARS-CoV-2 mRNA vaccine.

Methods

We performed a telephone interview collecting any adverse event (AE) following immunization (AEFI) that occurred in RMD patients and healthy controls after the two doses of mRNA vaccine including common local reactogenicity and systemic events (for example, fever, fatigue/malaise, joint and muscle pain). We also investigated the onset of new signs or symptoms of the RMD after the vaccination.

Results

We evaluated 126 patients with RMDs [105 females and 19 males, median age 51(IQR 17

SUBMITTER: Spinelli FR 

PROVIDER: S-EPMC8748531 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature